SAN DIEGO--(BUSINESS WIRE)--BioDuro, LLC, a leading global life sciences contract research, development and manufacturing services organization, is pleased to announce the appointment of Kent Payne, Ph.D., as President of its CMC Global Solutions business unit. Kent has extensive executive and operational experience in the CDMO market and has successfully managed start-up to well established growth business interests in both Fortune 500 and Private Equity environments.
“BioDuro’s mission in the contract research and outsourced services marketplace is to provide seamless connectivity from early stage drug discovery through IND-enabling studies, formulation development and scale up manufacturing,” said Cyrus K. Mirsaidi, CEO, BioDuro. “Kent’s addition as President to our executive team, and his extensive experience to grow businesses both organically and through M&A, will enable BioDuro to continue to focus as a full service solution provider to our current client base and help grow that client reach with new and expanded offerings.”
Kent is a distinguished business operator and leader in areas of sales, commercial manufacturing and product development. He combines strong business leadership skills, proven successful P&L track records, and a solid scientific and technical background to strategically lead and grow enterprise value across Biotechnology and Pharmaceutical market segments. Over the last 20 years, he has successfully led the geographic expansion of businesses into Europe, Asia, South America in addition to the United States.
After earning his Ph.D. in Analytical Chemistry from Brigham Young University, Kent went on to hold positions of progressive leadership responsibility at Novartis, Monsanto and G.D. Searle.
Kent currently serves as a board member for Goodwin Biotechnologies (a biological contract manufacturer), and as a board advisor for Vitruvias Therapeutics (a specialty generic pharmaceutical business). He held prior Board and Advisory roles at Life Science Institute Inc. (a wholly-owned subsidiary of Mitsubishi Chemical Holdings), Technophar, Inc., Qualicaps, Inc. and PDS Biotechnology (PDSB).
Prior to joining BioDuro, Kent was CEO at Socorro Pharmaceuticals, a generic pharmaceutical company. He also served as President Americas at Qualicaps Inc. and as Principal Consultant and Partner at CoreFactor LLC, providing executive strategic, licensing and operational advisory services to clients and as Vice President/General Manager at Catalent Pharma Solutions, Inc. (a Blackstone Group company formed in 2007, formerly part of Cardinal Health).
“I am pleased to join BioDuro,” said Kent Payne, Ph.D., President, BioDuro Global CMC Solutions. “And to work alongside the executive team and Advent International, to continue the culture of customer focus while expanding BioDuro’s technical offering.”
BioDuro is a leading, global life sciences contract research, development and manufacturing organization that provides biopharmaceutical clients and partners with comprehensive, fully integrated drug discovery services spanning target identification to IND filing, through to cGMP manufacture of drug product for clinical trials. With depth and breadth of therapeutic expertise in small and large molecule discovery, development and scale up, combined with unique technology platforms such as high content 3D drug screening, in-vivo translational models, and bioavailability enhancement of insoluble compounds, BioDuro is well positioned to help biopharmaceutical partners significantly accelerate their lead discovery programs, and de-risk development programs for higher value outcomes. Visit www.bioduro.com.
About Advent International
Founded in 1984, Advent International is one of the largest and most experienced global private equity investors. The firm has invested in over 350 private equity transactions in 41 countries and as of June 30, 2019 it had $54.3 billion in assets under management. With offices on four continents, Advent has established a globally integrated team of more than 200 investment professionals across North America, Europe, Latin America and Asia. The firm focuses on investments in five core sectors: including business and financial services, healthcare, industrial, retail, consumer and leisure, and technology, media and telecom. After more than 35 years dedicated to international investing, Advent remains committed to partnering with management teams to deliver sustained revenue and earnings growth for its portfolio companies.
For more information, visit www.adventinternational.com